Literature DB >> 18828948

Harmonization of evidence requirements for health technology assessment in reimbursement decision making.

John Hutton1, Paul Trueman, Karen Facey.   

Abstract

As more countries use HTA to inform decisions on the reimbursement of health technologies, harmonization of evidence requirements between jurisdictions has been proposed, mainly on the grounds of improved efficiency. Harmonization has the potential to avoid duplication of effort for both manufacturers and HTA bodies involved in preparing and reviewing HTA submissions for innovative technologies. However, it also carries risks of loss of local control over decisions, the application of general data standards which are not universally accepted and slowing the rate of development of innovation in the analytical disciplines supporting HTA. This study reviews the issues associated with harmonization taking into account the perspectives of the multiple stakeholders. This study draws on experiences from recent initiatives intended to promote the harmonization of HTA and experience from related fields, particularly regulatory approval of new medical technologies.

Entities:  

Mesh:

Year:  2008        PMID: 18828948     DOI: 10.1017/S0266462308080677

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  8 in total

1.  Potential benefits of using a toolkit developed to aid in the adaptation of HTA reports: a case study considering positron emission tomography (PET) and Hodgkin's disease.

Authors:  Sheila Turner; Neil Adams; Andrew Cook; Alison Price; Ruairidh Milne
Journal:  Health Res Policy Syst       Date:  2010-05-26

2.  Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia.

Authors:  Na Zhou; Hong Ji; Zheng Li; Jun Hu; Jia-Hua Xie; Yu-Heng Feng; Ni Yuan
Journal:  Front Public Health       Date:  2022-06-17

3.  Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.

Authors:  Mireille M Goetghebeur; Monika Wagner; Hanane Khoury; Donna Rindress; Jean-Pierre Grégoire; Cheri Deal
Journal:  Cost Eff Resour Alloc       Date:  2010-04-08

4.  Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.

Authors:  Michèle Tony; Monika Wagner; Hanane Khoury; Donna Rindress; Tina Papastavros; Paul Oh; Mireille M Goetghebeur
Journal:  BMC Health Serv Res       Date:  2011-11-30       Impact factor: 2.655

5.  Pharmaceutical companies' views on a health technology assessment (HTA) entity in Saudi Arabia.

Authors:  Hussain Abdulrahman Al-Omar; Abdulaziz Abdulhadi Attuwaijri; Ibrahim Abdulrahman Aljuffali
Journal:  Saudi Pharm J       Date:  2020-04-23       Impact factor: 4.330

6.  Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions.

Authors:  Daryl S Spinner; Julie Birt; Jeffrey W Walter; Lee Bowman; Josephine Mauskopf; Michael F Drummond; Catherine Copley-Merriman
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-30

Review 7.  Health technology assessment in osteoporosis.

Authors:  Mickael Hiligsmann; John A Kanis; Juliet Compston; Cyrus Cooper; Bruno Flamion; Pierre Bergmann; Jean-Jacques Body; Steven Boonen; Olivier Bruyere; Jean-Pierre Devogelaer; Stefan Goemaere; Jean-Marc Kaufman; Serge Rozenberg; Jean-Yves Reginster
Journal:  Calcif Tissue Int       Date:  2013-03-21       Impact factor: 4.333

Review 8.  Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges.

Authors:  Richard Ofori-Asenso; Christine E Hallgreen; Marie Louise De Bruin
Journal:  Front Med (Lausanne)       Date:  2020-10-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.